http://www.cs.purdue.edu/homes/cmh/cancer2.htm
http://www.texasoncology.com/types-of-cancer/pancreatic-cancer/stage-iv-pancreatic-cancer/
Although it appears that more patients respond to combination treatment than single-agent treatment, only Tarceva has been demonstrated to improve survival when combined with Gemzar in a direct comparison. It has not been determined whether patients who receive other combinations live longer than those who receive single-agent Gemzar or Gemzar combined with Tarceva (see table 1). This is because the clinical trials evaluating the combinations in Table 1 have not been directly compared to single-agent Gemzar in a controlled clinical trial.
Table 1 Results from seven trials that evaluated different chemotherapy regimens in the treatment of advanced pancreatic cancer
*patients with locally-advanced disease (IVA)
**patients with metastatic disease (IVB)
***not measured in this trial